
Loading, please wait...

Loading, please wait...

VEXAS syndrome represents a distinct hemato-inflammatory disorder caused by acquired somatic mutations in hematopoietic stem cells. Specifically, mutations affect the X-linked UBA1 gene, which encodes the critical ubiquitin-activating enzyme 1. This essential enzyme normally initiates intracellular ubiquitination, directing damaged proteins toward proteasomal degradation. Consequently, loss of canonical enzyme function disrupts cytoplasmic homeostasis and triggers severe endoplasmic reticulum stress. In response, aberrant myeloid progenitor cells hyperactivate innate immune pathways, causing excessive production of inflammatory cytokines. Because UBA1 resides on the X chromosome, this disorder almost exclusively impacts adult men aged fifty years or older. However, clinicians occasionally identify rare female cases associated with acquired X-chromosome monosomy. Unlike inherited germline conditions, these somatic alterations emerge spontaneously during adulthood. Furthermore, mutated hematopoietic clones exhibit preferential myeloid differentiation, leading to clonal dominance within the bone marrow. As a result, patients develop refractory cytopenias, particularly progressive macrocytic anemia and thrombocytopenia. Ultimately, this convergence of somatic clonal hematopoiesis and unrelenting autoinflammation produces widespread organ damage, establishing a crucial link between rheumatology and hematology.
Patients exhibit a remarkably wide spectrum of systemic symptoms, frequently leading to diagnostic confusion. Recurrent, unprovoked fevers of unknown origin often represent the initial clinical manifestation. In addition, cutaneous involvement occurs in nearly ninety percent of affected individuals. Dermatologists frequently identify painful neutrophilic dermatoses, leukocytoclastic vasculitis, periorbital edema, and tender erythematous plaques. Furthermore, relapsing chondritis affecting the ears and nose represents another classical physical finding. Patients also experience debilitating constitutional fatigue, unintended weight loss, and severe inflammatory polyarthritis. Moreover, pulmonary complications contribute significantly to overall patient morbidity. Clinicians regularly detect persistent dry cough, progressive dyspnea, pleural effusions, and sterile pulmonary infiltrates on high-resolution computed tomography. In addition, vascular abnormalities present grave, life-threatening risks to affected individuals. Specifically, patients demonstrate a striking predisposition to unprovoked venous thromboembolism, including recurrent deep vein thrombosis and pulmonary embolism. Ocular inflammation, such as episcleritis, scleritis, and anterior uveitis, also occurs frequently. Because these protean manifestations involve multiple organ systems simultaneously, patients often endure years of misdirected consultations before receiving an accurate diagnosis.
Achieving a timely diagnosis requires high clinical suspicion alongside coordinated hematologic and genetic evaluations. Routine baseline laboratory testing consistently reveals profound systemic inflammation, including marked elevations in C-reactive protein and erythrocyte sedimentation rate. In addition, peripheral blood evaluation demonstrates characteristic hematologic abnormalities. Clinicians typically observe progressive macrocytic anemia with elevated mean corpuscular volume, alongside lymphopenia, monocytopenia, and thrombocytopenia. When physicians suspect the disease, bone marrow aspiration and biopsy provide critical diagnostic evidence. Specifically, hematopathologists observe distinct, non-specific cytoplasmic vacuoles within erythroid and myeloid precursor cells. These diagnostic vacuoles selectively affect early precursor lineages while sparing mature granulocytes and lymphocytes. However, definitive confirmation strictly requires targeted molecular genetic analysis. Clinicians should request targeted DNA sequencing or next-generation sequencing panels to detect somatic UBA1 mutations, particularly at codon 41. Because variant allele frequencies remain high in circulating leukocytes, standard peripheral blood testing reliably identifies the pathogenic variant. Therefore, clinicians can secure a definitive diagnosis rapidly without resorting to invasive tissue biopsies, preventing harmful treatment delays and guiding appropriate management.
The complex clinical presentation frequently mimics several established rheumatologic, infectious, and hematologic disorders. In particular, clinicians often misclassify affected patients as having classic myelodysplastic syndrome. Indeed, approximately forty percent of these patients meet morphological bone marrow criteria for myelodysplastic neoplasms. Similarly, rheumatologists frequently diagnose individuals with relapsing polychondritis, polyarteritis nodosa, giant cell arteritis, or Sweet syndrome. For instance, ear cartilage inflammation closely resembles relapsing polychondritis, yet standard immunosuppressive regimens provide minimal benefit. Furthermore, recurrent unexplained fevers regularly trigger exhaustive diagnostic searches for occult infectious diseases, such as tuberculosis, brucellosis, and infectious endocarditis. Unlike traditional autoimmune disorders, patients with this syndrome routinely test negative for autoantibodies, including antinuclear antibodies and antineutrophil cytoplasmic antibodies. Therefore, persistent seronegativity in the presence of severe systemic inflammation should alert astute clinicians. Moreover, progressive macrocytic cytopenias strongly suggest clonal myeloid disease rather than uncomplicated autoimmune pathology. Consequently, discerning these distinctive clinical nuances enables healthcare providers to differentiate this autoinflammatory disorder from benign mimics and avoid unnecessary, repetitive diagnostic testing.
Managing this complex hemato-inflammatory condition requires a balanced strategy targeting both hyperinflammation and the pathogenic myeloid clone. Initially, high-dose oral corticosteroids provide prompt symptomatic control and suppress acute systemic inflammation. However, patients almost universally develop corticosteroid dependence, experiencing debilitating inflammatory relapses during dose tapering. Furthermore, conventional synthetic disease-modifying antirheumatic drugs, including methotrexate, cyclosporine, and azathioprine, exhibit remarkably poor clinical efficacy. Consequently, specialists increasingly utilize targeted biologic agents and small-molecule inhibitors to maintain disease remission. In particular, Janus kinase inhibitors, such as ruxolitinib, demonstrate encouraging results by suppressing cytokine signaling cascades and reducing transfusion dependency. Similarly, interleukin-6 receptor inhibitors offer effective inflammatory control in selected individuals. In patients with significant bone marrow involvement or progressive cytopenias, hypomethylating agents like azacitidine suppress the mutated hematopoietic clone effectively. Additionally, allogeneic hematopoietic stem cell transplantation represents the only curative therapeutic option for eligible patients with advanced disease. Finally, comprehensive management mandates rigorous supportive care, including routine prophylaxis against venous thromboembolism, meticulous infection surveillance, and proactive bone health preservation.
Physicians should suspect this diagnosis whenever an older adult, particularly a male over fifty, presents with recurrent fever of unknown origin and treatment-refractory inflammation. Key signs include relapsing chondritis of the ears or nose, painful neutrophilic skin lesions, and sterile pulmonary infiltrates. Additionally, unexplained macrocytic anemia, persistent cytopenias, or unprovoked venous thromboembolism should heighten clinical vigilance. If conventional autoimmune serologies remain negative and high-dose steroids provide only transient relief, clinicians must immediately consider this syndrome.
Definitive confirmation relies on demonstrating characteristic bone marrow morphology and identifying a pathogenic somatic mutation in the UBA1 gene. Bone marrow aspirates typically display prominent cytoplasmic vacuolization within erythroid and myeloid precursor cells. Subsequently, clinicians must order targeted Sanger sequencing or next-generation sequencing on peripheral blood leukocytes. Detecting somatic missense or splice-site variants at codon 41 confirms the diagnosis without requiring skin biopsies, providing an objective genetic marker that distinguishes this condition from other autoinflammatory diseases.
Management requires balancing aggressive anti-inflammatory control with clone-directed interventions. High-dose oral corticosteroids provide initial symptom relief, but clinicians frequently encounter severe steroid dependency. Consequently, specialists prescribe steroid-sparing targeted agents, particularly Janus kinase inhibitors such as ruxolitinib or interleukin-6 antagonists. For patients with progressive cytopenias or myelodysplastic syndrome, hypomethylating agents like azacitidine suppress the mutated clone. Finally, allogeneic hematopoietic stem cell transplantation offers the sole curative therapeutic option in carefully selected candidates with progressive, treatment-refractory disease.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


VEXAS syndrome is a newly identified autoinflammatory disorder caused by somatic UBA1 mutations in hematopoietic stem cells. Characterized by cytopenias, fevers, and multi-organ inflammation, it requires bone marrow evaluation and genetic sequencing for definitive diagnosis and targeted management.
Today

A meta-analysis of 9 randomized controlled trials evaluated health-related quality of life when adding PD-1/PD-L1 inhibitors to standard therapy for endometrial and cervical cancer. Adding immunotherapy did not detectably change global quality of life or worsen functional and symptom domains.
Today

A cross-sectional study evaluates the critical intersection between acute surgical pain, kinesiophobia, and fall risks during initial mobilization after cardiac surgery, emphasizing targeted nursing strategies.
Today

A comprehensive meta-analysis reveals a decline in hip avascular necrosis following kidney transplantation to 3.45% post-2010. This decline reflects modern steroid-sparing immunosuppression, while highlighting geographic variations and the importance of early diagnosis.
Today

Single-cell transcriptomics reveals that STAP2 promotes retinal endothelial dysfunction in diabetic retinopathy through CXCR4 signaling. In vivo and in vitro studies show STAP2 knockdown reduces capillary drop-out and vascular leakage, uncovering a novel therapeutic target beyond anti-VEGF therapies.
Today